• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Applying Desirability of Outcome Ranking End Point to Randomized Trial of Sulopenem for the Treatment of Complicated Urinary Tract Infections.

作者信息

Dunne Michael W, Aronin Steven I, Das Anita F, Gupta Jayanti, Akinapelli Karthik, Breen Jeanne, Zelasky Michael T, Puttagunta Sailaja

机构信息

Iterum Therapeutics, Old Saybrook, Connecticut, USA.

Das Statistical Consulting, Guerneville, California, USA.

出版信息

Clin Infect Dis. 2023 Jun 16;76(12):2213-2215. doi: 10.1093/cid/ciad149.

DOI:10.1093/cid/ciad149
PMID:36949581
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10273356/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0676/10273356/5361770f59c7/ciad149f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0676/10273356/5361770f59c7/ciad149f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0676/10273356/5361770f59c7/ciad149f1.jpg

相似文献

1
Applying Desirability of Outcome Ranking End Point to Randomized Trial of Sulopenem for the Treatment of Complicated Urinary Tract Infections.将结局排序终点的合意性应用于舒洛培南治疗复杂性尿路感染的随机试验。
Clin Infect Dis. 2023 Jun 16;76(12):2213-2215. doi: 10.1093/cid/ciad149.
2
Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria.舒巴坦钠：一种用于治疗多重耐药菌引起的尿路感染的静脉注射和口服青霉素类药物。
Drugs. 2022 Apr;82(5):533-557. doi: 10.1007/s40265-022-01688-1. Epub 2022 Mar 16.
3
Improving Traditional Registrational Trial End Points: Development and Application of a Desirability of Outcome Ranking End Point for Complicated Urinary Tract Infection Clinical Trials.改进传统注册临床试验终点：复杂尿路感染临床试验结局排序终点的制定与应用。
Clin Infect Dis. 2023 Feb 8;76(3):e1157-e1165. doi: 10.1093/cid/ciac692.
4
Sulopenem for the Treatment of Complicated Urinary Tract Infections Including Pyelonephritis: A Phase 3, Randomized Trial.硫酸头孢噻肟治疗包括肾盂肾炎在内的复杂性尿路感染的 3 期随机试验。
Clin Infect Dis. 2023 Jan 6;76(1):78-88. doi: 10.1093/cid/ciac704.
5
Treatment of complicated urinary tract infection in adults: combined analysis of two randomized, double-blind, multicentre trials comparing ertapenem and ceftriaxone followed by appropriate oral therapy.成人复杂性尿路感染的治疗：两项随机、双盲、多中心试验的联合分析，比较厄他培南和头孢曲松随后进行适当口服治疗的效果。
J Antimicrob Chemother. 2004 Jun;53 Suppl 2:ii67-74. doi: 10.1093/jac/dkh208.
6
Sulopenem or Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infections in Women: A Phase 3, Randomized Trial.舒巴坦匹酯或环丙沙星治疗女性单纯性尿路感染的随机对照 3 期临床试验
Clin Infect Dis. 2023 Jan 6;76(1):66-77. doi: 10.1093/cid/ciac738.
7
Activity of Sulopenem, an Oral Penem, against Urinary Isolates of .硫培南对..尿分离株的活性。
Antimicrob Agents Chemother. 2018 Dec 21;63(1). doi: 10.1128/AAC.01832-18. Print 2019 Jan.
8
[Efficacy and safety of ciprofloxacin treatment in urinary tract infections (UTIs) in adults: a systematic review with meta-analysis].环丙沙星治疗成人尿路感染（UTIs）的疗效与安全性：一项系统评价与荟萃分析
Gac Med Mex. 2015 Mar-Apr;151(2):225-44.
9
In vitro activity of sulopenem against 1880 bacterial pathogens isolated from Canadian patients with urinary tract infections (CANWARD, 2014-21).在体外，硫酸头孢匹罗对 1880 株从加拿大泌尿道感染患者中分离的病原菌（CANWARD，2014-21 年）的活性。
J Antimicrob Chemother. 2022 Nov 28;77(12):3414-3420. doi: 10.1093/jac/dkac333.
10
Carbapenem-alternative strategies for complicated urinary tract infections: A systematic review of randomized controlled trials.复杂性尿路感染的碳青霉烯类替代策略：随机对照试验的系统评价
J Infect. 2020 Oct;81(4):499-509. doi: 10.1016/j.jinf.2020.08.008. Epub 2020 Aug 12.

本文引用的文献

1
Opening a DOOR for Pivotal Studies: An Example for Complicated Urinary Tract Infections.为关键研究打开一扇门：复杂尿路感染的一个例子
Clin Infect Dis. 2023 Feb 8;76(3):e1166-e1167. doi: 10.1093/cid/ciac778.
2
Sulopenem for the Treatment of Complicated Urinary Tract Infections Including Pyelonephritis: A Phase 3, Randomized Trial.硫酸头孢噻肟治疗包括肾盂肾炎在内的复杂性尿路感染的 3 期随机试验。
Clin Infect Dis. 2023 Jan 6;76(1):78-88. doi: 10.1093/cid/ciac704.
3
Improving Traditional Registrational Trial End Points: Development and Application of a Desirability of Outcome Ranking End Point for Complicated Urinary Tract Infection Clinical Trials.
改进传统注册临床试验终点：复杂尿路感染临床试验结局排序终点的制定与应用。
Clin Infect Dis. 2023 Feb 8;76(3):e1157-e1165. doi: 10.1093/cid/ciac692.
4
Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of America.美国传染病学会 2019 年无症状菌尿管理临床实践指南更新版。
Clin Infect Dis. 2019 May 2;68(10):1611-1615. doi: 10.1093/cid/ciz021.
5
Distribution-free confidence intervals for a parameter of Wilcoxon-Mann-Whitney type for ordered categories and progressive censoring.有序类别和渐进删失情形下Wilcoxon-Mann-Whitney型参数的无分布置信区间
Biometrics. 1989 Jun;45(2):509-21.